Navigation Links
OrbusNeich's Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents

HONG KONG, Dec. 2, 2010 /PRNewswire/ -- OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis.

The cumulative rate of the study's primary endpoint, the composite of cardiac death, myocardial infarction (MI) or target lesion revascularization (TLR) at one year follow-up, was 12.4% in patients treated with a Genous Stent, a 30% reduction compared to 17.2% for the control group treated with BMS.  The definite or probable stent thrombosis (ST) rate was 1.7% for the Genous Stent patient group, compared to 3.4% for the BMS treated patient group.

"Interventional cardiologists continue to be challenged by the 15 to 20% of all percutaneous coronary interventions that involve coronary artery bifurcation lesions," said Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, the lead author of the paper. "The results of this large study of provisional T-stenting using the Genous Stent are extremely encouraging. The endothelial progenitor cell capture stent provides an excellent alternative to bare metal stents for the treatment of these challenging lesions."

The paper, titled "One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent," is based on a single-center, non-randomized study. The study involved 178 consecutive patients who underwent percutaneous coronary intervention for a de novo bifurcation lesion treated with a Genous Stent and 465 consecutive patients treated with BMS.

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which  has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, Sapphire™ and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
2. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
3. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
4. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
5. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
6. Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent
9. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
10. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
11. Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market
Post Your Comments:
(Date:10/13/2015)... EDISON, N.J. , Oct. 13, 2015 /PRNewswire/ ... or the "Company"), a biopharmaceutical company focused on ... today announced the closing of its previously announced ... common stock and warrants to purchase up to ... a fixed combined price to the public of ...
(Date:10/13/2015)... 2015  Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... today the launch of the company,s first Health Nucleus, ... potential to transform healthcare. The inaugural Health Nucleus is ... at HLI,s headquarters facility. More Health Nucleus facilities are ... International cities. --> ...
(Date:10/13/2015)... 2015  Measurement in accountable care programs is ... incentives, but gaps in measurement can result in ... systems. A new, peer-reviewed study published in ... explores measurement gaps for high-priority conditions and ... --> --> "These gaps ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to ... be held March 2nd and 3rd, 2016. The annual meeting, along with the ... physicians from around the world. , Key topics at this year's event will include ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... 13, 2015 , ... NavaFit Inc. today announced the launch of its NavaFit ... participate in local fitness & sporting events, and stay motivated. Users can ... costs drive us to get more serious about fitness and wellness, individuals are constantly ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value of ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... and the University of British Columbia found that certain genetic alterations were seen just ...
Breaking Medicine News(10 mins):